Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hanmi Pharmaceutical Company Limited
A randomized, double-blind, multicenter, phase 3 study to evaluate efficacy and safety of HCP1401 for stage 2 hypertension patients not controlled by HCP0605
Age
19–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Hypertension patient who satisfied below condition at Visit 1.
* patient who takes antihypertensive drug
* 140mmHg \<= sitSBP \<= 200mmHg
* patient who doesn't take antihypertensive drug
* 160mmHg \<= sitSBP \<= 200mmHg
* 140mmHg \<= sitSBP \<= 200mmHg at Visit 2
You may not be if
Patient who have received 4 or more antihypertensive drug
Patient with 20mmHg of difference in sitSBP or 10mmHg of difference in sitDBP between 3 times of BP measuring at Visit 1
